<DOC>
	<DOCNO>NCT02440802</DOCNO>
	<brief_summary>Androgen deprivation therapy ( ADT ) surgical castration administration LHRH agonists antagonists gold-standard systemic treatment Prostate Cancer . The efficacy , severity frequency side effect ADT vary patient another . The exact cause variability know , however certain genetic polymorphism affect enzymes implicate synthesis metabolism sex-steroids seem involve process . To perform longitudinal study evaluate prevalence various genetic polymorphism affect gene sex-steroid synthesis metabolism pathway ( CYP1A1 , CYP1B1 , CYP19A1 , 17HSD , HSD3B1 , AR , ESR1 , ESRRG , IL6 , TNF-alpha ) men Prostate Cancer receive ADT possible association polymorphism frequency severity side-effects ADT .</brief_summary>
	<brief_title>Evaluation Predictive Value Genetic Polymorphisms Management Hormonal Treatment Prostate Cancer</brief_title>
	<detailed_description>Prostate cancer patient reimburse ADT gonadoliberin antagonist indicate , period least 6 month lbe enrol . At 0 , 3 month 6 month ADT , Aging Males ' Symptoms ( AMS ) , EQ-5D ( EuroQoL ) , hot flash intensity frequency ( Moyad scale ) collect , well routine assessment : vital sign ( blood pressure , heart rate ) , weight , waist perimeter , fat percentage , Body Mass Index ( BMI ) routine laboratory assessment . Determine genotypes polymorphisms interest pyrosequencing . Determine prevalence polymorphisms interest study population . Perform initial assessment association genetic polymorphism questionnaire result .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Prostate cancer patient reimburse ADT gonadoliberin antagonist indicate , period least 6 month . Prostate cancer patient already receive ADT gonadoliberin antagonist .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>